Axon Enterprise, Inc $AXON Shares Bought by Valeo Financial Advisors LLC

Valeo Financial Advisors LLC raised its position in Axon Enterprise, Inc (NASDAQ:AXON) by 4.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 987 shares of the biotechnology company’s stock after buying an additional 38 shares during the period. Valeo Financial Advisors LLC’s holdings in Axon Enterprise were worth $817,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of AXON. Brighton Jones LLC acquired a new stake in Axon Enterprise in the 4th quarter worth about $480,000. Wedmont Private Capital boosted its holdings in shares of Axon Enterprise by 22.8% during the 1st quarter. Wedmont Private Capital now owns 825 shares of the biotechnology company’s stock worth $469,000 after purchasing an additional 153 shares during the last quarter. Capital Investment Advisors LLC boosted its holdings in shares of Axon Enterprise by 86.5% during the 1st quarter. Capital Investment Advisors LLC now owns 1,285 shares of the biotechnology company’s stock worth $676,000 after purchasing an additional 596 shares during the last quarter. Yousif Capital Management LLC boosted its holdings in shares of Axon Enterprise by 1.6% during the 1st quarter. Yousif Capital Management LLC now owns 9,961 shares of the biotechnology company’s stock worth $5,239,000 after purchasing an additional 157 shares during the last quarter. Finally, Harbor Capital Advisors Inc. acquired a new position in shares of Axon Enterprise during the 1st quarter worth approximately $587,000. 79.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on AXON. Wolfe Research began coverage on Axon Enterprise in a report on Monday, July 7th. They set an “outperform” rating on the stock. UBS Group restated a “neutral” rating and set a $840.00 target price (up from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Zacks Research cut Axon Enterprise from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 2nd. Needham & Company LLC restated a “buy” rating and set a $870.00 target price on shares of Axon Enterprise in a report on Wednesday, September 24th. Finally, Northland Securities set a $800.00 target price on Axon Enterprise in a report on Tuesday, August 5th. Fourteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $841.64.

Axon Enterprise Stock Up 1.8%

AXON stock opened at $727.41 on Thursday. The firm has a market cap of $57.10 billion, a PE ratio of 179.61, a PEG ratio of 27.75 and a beta of 1.41. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The firm’s 50 day moving average price is $756.79 and its 200-day moving average price is $710.65. Axon Enterprise, Inc has a one year low of $422.21 and a one year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, beating the consensus estimate of $1.54 by $0.58. The firm had revenue of $668.54 million for the quarter, compared to analyst estimates of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business’s revenue for the quarter was up 32.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Insider Buying and Selling

In other Axon Enterprise news, CFO Brittany Bagley sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $713.88, for a total value of $3,569,400.00. Following the sale, the chief financial officer owned 93,592 shares of the company’s stock, valued at $66,813,456.96. The trade was a 5.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Jeri Williams sold 100 shares of the business’s stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $752.54, for a total value of $75,254.00. Following the completion of the sale, the director directly owned 1,416 shares in the company, valued at approximately $1,065,596.64. The trade was a 6.60% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 59,932 shares of company stock valued at $45,115,616 over the last quarter. 4.40% of the stock is owned by corporate insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.